Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
RCUS
Home
/
RCUS

NYSE
$19.31
$19.31

Overview

Price performance
Low
$18.60
High
$19.61
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
19.31
0.40 (2.12%)
Average, 50 days
$24.50
$24.63
Open
$19.51
Previous close
$18.91
52-week high
$31.74
Jun 30, 2026 (5 months ago)
52-week low
$17.43
Oct 22, 2026 (15 days ago)
10.79%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
2.43B
Volume
2 076 185
Total Return (3M)
-32.95%
Total Return (1Y)
-2.62%
16.90
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NYSE
US
Website
arcusbio.com
About
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Frequently asked questions

RCUS · Arcus Biosciences, Inc.

01What is Arcus Biosciences, Inc. stock price today?

The current price of RCUS is $19.31 — it has increased by 2.12% since the previous close. Data as of Nov 4, 2026.

02Is Arcus Biosciences, Inc. stock price growing?

RCUS is up 5.29% over the past week, down 20.99% over the past month and down 2.62% over the past year. The price is below its 200-day moving average of $24.63.

03What is RCUS stock forecast?

Analysts' average 12-month price target for RCUS is $38.80, which implies 100.93% upside from the current price. Individual estimates range from $23.00 to $45.00.

04What do analysts say about RCUS stock?

Of the 15 analysts covering Arcus Biosciences, Inc., 1 rates it a strong buy, 12 rate it a buy and 2 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

05What is Arcus Biosciences, Inc. market cap?

Arcus Biosciences, Inc. has a market capitalization of $2.43B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

06What were Arcus Biosciences, Inc. earnings last quarter?

In its most recent quarterly report, Arcus Biosciences, Inc. posted a loss of $0.72 per share against an estimate of -$0.8912, beating expectations by 19.21%. Upcoming reports are listed in the earnings calendar.

07What is Arcus Biosciences, Inc. revenue for the last quarter?

Arcus Biosciences, Inc. reported revenue of $41M in its most recent quarter, which has decreased by 74.38% compared with the same quarter a year earlier. Analysts had expected $21.98M.

08Does Arcus Biosciences, Inc. pay dividends?

Arcus Biosciences, Inc. has not paid any dividends over the past year.

09Who are Arcus Biosciences, Inc. competitors?

Companies most comparable to Arcus Biosciences, Inc. include ImmunityBio, Inc., Cogent Biosciences, Inc., Liquidia Corporation, Denali Therapeutics Inc. and Viridian Therapeutics, Inc.

10How volatile is RCUS stock?

In the latest trading session RCUS moved between $18.60 and $19.61, a range of 5.23% of its current price.

11Should I invest in Arcus Biosciences, Inc. stock?

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Arcus Biosciences, Inc. shows a sell rating today and a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.

12What are RCUS stock 52-week high and low?

Over the past 52 weeks RCUS has traded between $17.43 and $31.74. The current price is 39.16% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.